THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人:
SARNOW, PETER,JOPLING, CATHERINE L.,LANCASTER, ALISSA M.
申请号：
CA2564503
公开号：
CA2564503C
申请日:
2005.05.03
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
Provided herein are compositions and methods for treating HCV-mediateddisease conditions employing antisense oligonucleotides as miR122 inhibitoryagents. It was discovered herein that the ability of HCV to replicate indifferenthuman liver cell lines correlates with the levels of miR122 in those celllines； thatthe HCV genome contains sequences that are complementary to miR122； and thatinhibiting miR122 activity in HCV-infected liver cells using antisenseoligonucleotides can dramatically reduce the level of HCV replication.
